nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

Lens profiles as Ez (orange lines) force was increased and Az and Pz (green lines) forces were decreased. by Ronald A. Schachar (16674576)

Algorithm operation steps. by Junyan Wang (4738518)

“…Experimental results demonstrate that SCI-YOLO11 achieves a 3.2% improvement over baseline models in terms of MAP@0.5 metric; precision and recall rates increase by 2.6% and 3.7%, respectively. Additionally, its parameter count and floating-point operations decrease by 6% and 7.9%, respectively. …”

Water Withdrawal and Consumption Trends for Thermoelectric-Power Plants in the Conterminous United States, 2008–2020 by Kenneth D. Skinner (22280459)

Subjects:

Simulated regional mean wetland seasons. by Nic Gedney (19762301)

Subjects:

Regional contemporary (1990–1999 mean) precipitation and JULES inundation fraction over the Amazon basin. by Nic Gedney (19762301)

Subjects:

Changes in decadal precipitation and JULES inundation between 1990–1999 and 2089–2098. by Nic Gedney (19762301)

Subjects:

Contemporary mean inundation fraction in the Amazon basin. by Nic Gedney (19762301)

Subjects:

Conformational Role of Methyl in the Potency of Cyclohexane-Substituted Squaramide CCR6 Antagonists by Brian S. Gerstenberger (1936534)

“…Herein we report the design of a potent CCR6 antagonist capable of inhibiting the chemotactic migration of CCR6⁺ T cells in vitro. …”

Conformational Role of Methyl in the Potency of Cyclohexane-Substituted Squaramide CCR6 Antagonists by Brian S. Gerstenberger (1936534)

“…Herein we report the design of a potent CCR6 antagonist capable of inhibiting the chemotactic migration of CCR6⁺ T cells in vitro. …”

Conformational Role of Methyl in the Potency of Cyclohexane-Substituted Squaramide CCR6 Antagonists by Brian S. Gerstenberger (1936534)

“…Herein we report the design of a potent CCR6 antagonist capable of inhibiting the chemotactic migration of CCR6⁺ T cells in vitro. …”

Innovation, nightlights and a continuous measure of city size. by Saul Estrin (8629173)

Subjects:

Raw data 6–9 and 15. by Fateme Khorramroo (18086501)

Comparison of diffusion simulations: implicit scheme of the GDE with a 30-second time step (blue line), implicit scheme of the PNGM with α = 0.6 and a 15-second time step (green li... by Mouad Klai (20818364)

In the first 15 days of pod fill high temperature over 30∘C decreased marketable yield for both seasons. by Miranda Y. Mortlock (20855564)

Large Hyperfine Coupling Arising from Pseudo‑²S Ground States in a Series of Lutetium(II) Metallocene Complexes by Danh X. Ngo (6110606)

“…To our knowledge, this degree of s-character in a molecular orbital is the largest yet reported for an open-shell isolable complex. …”

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Largest changes in influenza vaccine rates, Pre- vs. Post-COVID-19. by Tyler B. Nofzinger (21560244)

Subjects:

Uganda 2023 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

“…The risk factor prevalences that increased significantly were: high blood glucose from 1.5% in 2014 to 3.3% in 2023 (p< 0.001); overweight and obesity from 19.3% in 2014 to 24.1% in 2023 (p< 0.001); current alcohol consumption from 28.5% in 2014 to 31.1% in 2023 (p=0.013); and sedentariness from 26.6% in 2014 to 31.9% in 2023 (p< 0.001). The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”

Uganda 2014 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

“…The risk factor prevalences that increased significantly were: high blood glucose from 1.5% in 2014 to 3.3% in 2023 (p< 0.001); overweight and obesity from 19.3% in 2014 to 24.1% in 2023 (p< 0.001); current alcohol consumption from 28.5% in 2014 to 31.1% in 2023 (p=0.013); and sedentariness from 26.6% in 2014 to 31.9% in 2023 (p< 0.001). The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”